ELIANA: What the Leukemia Trial Found

Why anyone built this trial

Acute lymphoblastic leukemia is a cancer of immature white blood cells. It is usually shortened to ALL, and it is the most common cancer in children.

Most children with ALL do well. NCI reports that the five-year survival rate for children under 15 rose from about 60% in the mid-1970s to roughly 90% by 2020. Our overview of childhood leukemia covers how that treatment works.

The hard cases are the ones that come back. When ALL returns a second time, or never clears at all, standard chemotherapy rarely holds it for long. ELIANA was built for that group.

What tisagenlecleucel actually is

Tisagenlecleucel is a CAR T-cell therapy. CAR stands for chimeric antigen receptor.

It is not a drug in the usual sense. It is made from the patient's own cells.

A machine filters T cells out of the blood. T cells are the immune system's attack cells. A lab then inserts a gene into them. That gene tells each cell to build a new receptor on its surface. The receptor locks onto CD19, a protein found on B cells — including leukemia B cells.

The changed cells are grown into the millions, frozen, then thawed and infused back. Our guide to CAR T-cell therapy walks through each step.

The design, and what it leaves out

ELIANA ran at 25 centers worldwide. Its ClinicalTrials.gov record, NCT02435849, lists it as a phase 2 study with a single group and no masking.

That matters. There was no comparison arm. Everyone got the same treatment.

Seventy-five children and young adults received an infusion and could be assessed. All had CD19-positive B-cell ALL that had come back or had not responded to earlier treatment.

What the trial reported

The main measure was overall remission within three months. Eighty-one percent reached it.

Everyone who responded was also negative for minimal residual disease on flow cytometry. Minimal residual disease means leukemia cells too few to see under a microscope but still findable by sensitive lab tests. Flow cytometry is one of those tests.

At six months, 73% were alive with no event and 90% were alive. At twelve months those figures were 50% and 76%. The median length of remission was not reached. That phrase means fewer than half had relapsed when counting stopped, so there was no midpoint to report.

The modified cells were still detectable in blood as long as 20 months after infusion.

What it costs the body

Severe side effects were the rule here, not the exception. Grade 3 or 4 events thought to be caused by the treatment occurred in 73% of patients.

Cytokine release syndrome affected 77%. That is a body-wide inflammatory reaction driven by signaling proteins the activated T cells release. It can bring high fever, low blood pressure, and organ strain. Forty-eight percent needed tocilizumab, a drug that blocks one of those signals.

Neurological events occurred in 40%. They were managed with supportive care, and no brain swelling was reported.

When to get checked

After CAR T-cell therapy, the warning window is short. Fever is the signal that matters most. A new fever or shaking chills after CAR T-cell therapy is a medical emergency — call the treatment center immediately, at any hour, and say what treatment you have had. Confusion, trouble breathing, or fainting mean emergency care now: call 911 or go to an emergency room, and tell them about the CAR T-cell therapy.

For a child not yet diagnosed, NCI's patient summary lists what should prompt a visit: fever, easy bruising or bleeding, flat pinpoint dark-red spots under the skin, weakness, pale skin, bone or joint pain, shortness of breath, painless swollen lymph nodes in the neck or armpit or groin, pain or fullness below the ribs, appetite or weight loss, and infections that keep returning.

Those symptoms have many causes, and most are not cancer. A blood count is how the question gets answered.

Where this sits now

The FDA licensed tisagenlecleucel on 30 August 2017, under the brand name Kymriah. FDA's product record lists it for patients up to 25 years of age with B-cell precursor ALL that is refractory, or in a second or later relapse. It was the first gene therapy of any kind cleared in the United States.

The American Cancer Society expects about 6,250 new ALL diagnoses and 1,600 deaths in the United States in 2026, and SEER, the federal cancer surveillance program, carries that estimate. Just over half of new cases are in people under 20. Five-year relative survival, an NCI registry measurement, was 73.2% for people diagnosed from 2016 through 2022. That figure pools every age and every risk group. It describes a population, not any one child.

What this trial cannot tell you

There was no control group. So the 81% remission rate cannot be lined up against anything else. It stands alone.

The 75 patients in the efficacy figures are not everyone who enrolled. People whose cells could not be manufactured, or who got sicker or died before infusion, are not in that denominator. A true intention-to-treat count would look worse.

Follow-up ran to 12 months in this report, and half the group had an event by then. Durability past that point was not a question this analysis could answer.

Participants were also selected. They were well enough to travel to one of 25 centers, well enough to wait weeks for manufacturing, and had one specific CD19-positive disease. Our page on clinical trial phases explains what a phase 2 result can and cannot settle.

Sources

• Maude SL et al., Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia, N Engl J Med 2018 (NCBI E-utilities record)
• FDA: KYMRIAH (tisagenlecleucel) product record, STN 125646
• ClinicalTrials.gov record for NCT02435849 (ELIANA)
• NCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (Health Professional Version)
• NCI PDQ: Childhood Acute Lymphoblastic Leukemia Treatment (Patient Version)
• NCI SEER Cancer Stat Facts: Acute Lymphocytic Leukemia

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.